Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease

Abstract

The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn’s disease has been evaluated. Thirty-two patients with Crohn’s disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn’s disease. However, in view of the product’s cost, further controlled studies are needed to confirm these preliminary data.

DOI: 10.1023/A:1005588911207

1 Figure or Table

Showing 1-10 of 19 references

Controlled trial of oral 5-aminosalycilic acid for the prevention TABLE 1

  • R De Franchis, P Omodei, +13 authors G Meucci
  • 2000
Showing 1-10 of 84 extracted citations
05001000'03'05'07'09'11'13'15'17
Citations per Year

4,818 Citations

Semantic Scholar estimates that this publication has received between 2,563 and 8,129 citations based on the available data.

See our FAQ for additional information.